Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 29Lymphoma 11Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Leukemia, B-Cell 8Recurrence 7Lymphoma, Large B-Cell, Diffuse 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Lymphoma, Mantle-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2Thrombocytopenia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Melanoma 1Lymphoma, B-Cell 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphoid 1Fever 1Fatigue 1Disease 1Bronchiolitis Obliterans Syndrome 1Agammaglobulinemia 1

Interventions

ibrutinib 3ruxolitinib 2asciminib 2Alemtuzumab 2sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1ofatumumab 1nilotinib 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1bosutinib 1belumosudil 1baricitinib 1axatilimab 1Voriconazole 1Tomography, X-Ray Computed 1Sofosbuvir 1Saline Solution 1SLC25A33 protein, human 1Rituximab 1Ribavirin 1Respiratory Function Tests 1Prednisone 1Pentostatin 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bronchiolitis Obliterans Syndrome × ofatumumab × Clear all
NCT02388048 2025-01-29

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed
19 enrolled
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡